跳至主要内容
临床试验/ACTRN12621000094875
ACTRN12621000094875尚未招募未知

Growth, body composition and developmental assessment of children conceived following a lipiodol hysterosalpingogram

niversity of Auckland, office of research strategy and integrity0 个研究点目标入组 100 人开始时间: 2021年2月1日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
6 Years 至 14 Years(—)
性别
All

入选标准

  • Exposure group: Children who are aged between 6-14 years, and have been conceived within 6 months of their mother receiving lipiodol hysterosalpingogram (HSG).
  • Control group: children who are aged between 6-14 years and are siblings of a child in the exposure group. They have been conceived without any assisted reproductive technology.

排除标准

  • Overt, pre-existing developmental delay.
  • Chronic illness that can impact on developmental assessment.
  • Medication known to affect neurocognitive outcome such as anti-depressives, methylphenidate etc.
  • A history of recreational drug use including tobacco and alcohol.
  • Known bone fragility disorders or medical conditions that could affect bone density.
  • Twins conceived following lipiodol.

研究者

发起方
niversity of Auckland, office of research strategy and integrity

相似试验